Actively Recruiting
Phase 1 Study of LY4298445 Safety and Tolerability in Healthy Adults and Adults With Systemic Lupus Erythematosus or Rheumatoid Arthritis
Led by Eli Lilly and Company · Updated on 2026-10-08
68
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of LY4298445 in both healthy adults and adults with systemic lupus erythematosus SLE or rheumatoid arthritis RA. This phase 1 study aims to understand how LY4298445 affects these groups over a period lasting up to about 52 weeks. The study is conducted with randomized and placebo-controlled groups to assess the drugs effects in a controlled setting. Participants receive LY4298445 either as single ascending doses SAD or multiple ascending doses MAD, delivered subcutaneously SC or intravenously IV depending on the group. Healthy participants receive single doses through SC or IV, while participants with SLE or RA receive single or multiple doses SC. There are also specific arms for healthy Japanese and optionally Chinese participants receiving single SC doses. During the study, participants undergo various assessments including monitoring for serious adverse events related to the drug, pharmacokinetic evaluations measuring drug concentration over time, and pharmacodynamic evaluations such as the degree of peripheral B cell depletion. The study lasts up to 52 weeks with follow-up for safety and drug effects, ensuring careful observation of participant health and drug impact throughout the trial.
CONDITIONS
Brief Title
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559)
P
Physicians interested in becoming principal investigators please contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here